



First Genetic-Based Breast Cancer Risk Test Broadly Applicable to Women Released to U.S. Commercial Market

OncoVue® Helps Women Evaluate Lifetime Risk of Developing Breast Cancer, Regardless of Family History

For Immediate Release:
November 13, 2007

For More Information Contact:
Jane Braden 405.818.1905

OKLAHOMA CITY—InterGenetics®, a personalized medicine company focused on molecular diagnostics and targeted therapy for cancer, announced the U.S. commercial release of OncoVue, the first genetic-based breast cancer risk test that incorporates both gene-based information and personal history measures to determine a woman’s future risk of developing breast cancer.

“OncoVue has just emerged from a 19-month, 19-city, FDA Investigational Device Exemption study. The data gathered from that study, in addition to the genetic information collected from more than 8,000 women in six geographic regions of the country over seven years of research, is the springboard for this commercial launch in the U.S.” said Dr. Craig Shimasaki, InterGenetics’ CEO/president. “InterGenetics’ clinical laboratory has passed all federal and state CLIA regulatory requirements necessary to introduce OncoVue into the commercial market. Additionally, although it is no longer a requirement for commercialization at this time, the company is continuing to work with the FDA for approval of the OncoVue test.”

OncoVue is now commercially available in the U.S. market through the InterGenetics Breast Cancer Risk Testing Network that is currently active in 13 states: Illinois, Maryland, Indiana, Arizona, Oklahoma, Kansas, Pennsylvania, Nevada, Michigan, Washington, Tennessee, Idaho and Texas.

The company is now expanding the number of testing centers and simultaneously raising additional working capital to effectively offer the test in other locations across the country. “We are excited to now be able to offer OncoVue to the public and look forward to the growth potential for our Oklahoma-based company and the future benefit to millions of women, and also to our shareholders who have supported this research over the past 14 years.”

OncoVue is the first genetic-based risk test relevant broadly applicable to women with or without a family history of the disease. It was developed from research examining genetic variants influencing breast cancer risk in women between 30

and 69 years of age. InterGenetics' core science and technology behind OncoVue is different from other genetic risk assessment tests available today. InterGenetics' research has created a testing algorithm that includes information from multiple genes that combined with personal history measures shown to have a significant relationship to risk of breast cancer. The OncoVue technology examines multiple genes that impact risk in the majority of women in contrast to the single gene mutations in the breast cancer genes BRCA 1 and BRCA 2 that significantly impact breast cancer risk, but are only relevant to five% or less of all breast cancers.

Breast cancer risk testing, in consultation with a medical provider, allows a woman identified at high risk, several options to consider. Many clinicians may incorporate lifestyle changes or use preventative medications currently on the market to prevent the disease, or include more comprehensive screening tools to diagnose cancer at its earliest stages where long term survival is the greatest.

The OncoVue test is easy for a woman to perform. First, she answers a simple medical history questionnaire, then swishes a commercial mouthwash and deposits the fluid into a tube. In the laboratory, DNA from the woman's cheek cells is analyzed, along with the data from the medical questionnaire to assign a numeric score that represents her risk of developing breast cancer at different stages of her life.

About InterGenetics

InterGenetics, is a personalized medicine company emerging as an innovator in the frontier of genetic medicine for cancer to improve women's health through genetics. The company's lead product, the OncoVue® Breast Cancer Risk Test, uses proprietary gene combinations and DNA assessment technology developed by InterGenetics' scientists. OncoVue can identify women who are at risk of developing breast cancer, potentially many years in advance of their diagnosis, where they can incorporate preventative strategies or catch the disease at its earliest stages where long term survival is the greatest.

InterGenetics has a promising research pipeline of predictive tests for other cancers such as ovarian, colon, prostate, and pancreatic cancer. The Company's core research includes preclinical testing for future application in targeted treatments for pancreatic cancer and end-stage lung cancer.

www.intergenetics.com